|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1993-12-7
|
|
pubmed:abstractText |
At a median time of 20 months following high dose melphalan for myeloma, 29 patients relapsed and were treated with induction chemotherapy to maximum response followed by a second course of high dose melphalan. The majority (90%) of patients received 200 mg m-2 with an autologous bone marrow transplant. Sixteen (55%) patients achieved complete remission and 11 (38%) a partial response. The median duration of remission was 17 (4-42) months. The median survival has not been reached, with 50% of patients alive at 58+ months after presentation. The period of neutropenia was similar during both first and second high dose procedures, but the duration of thrombocytopenia was longer in patients receiving melphalan for a second time (median 22 (16-56) days and 41 (18-69) days respectively). There was one treatment-related death due to thrombocytopenic haemorrhage. Repeated administration of high dose melphalan is a feasible approach for patients with relapsed myeloma.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-1922221,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-2184356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-2571813,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-2697587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-2902382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-3207601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-3532330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-3593657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-6137651,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-6176381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8217614-831755
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
983-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8217614-Adult,
pubmed-meshheading:8217614-Female,
pubmed-meshheading:8217614-Follow-Up Studies,
pubmed-meshheading:8217614-Humans,
pubmed-meshheading:8217614-Male,
pubmed-meshheading:8217614-Melphalan,
pubmed-meshheading:8217614-Middle Aged,
pubmed-meshheading:8217614-Multiple Myeloma,
pubmed-meshheading:8217614-Recurrence,
pubmed-meshheading:8217614-Survival Rate,
pubmed-meshheading:8217614-Time Factors
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Repeat administration of high dose melphalan in relapsed myeloma.
|
|
pubmed:affiliation |
CRC Section of Medicine, Institute of Cancer Research, Sutton, Surrey, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
